- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04181645
SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, single center, non-randomized, phase I trial to evaluate safety and efficacy of using the combination treatment of SHR-1210 with Paclitaxel-albumin and gemcitabine of metastatic PDAC.
PD-1 antibody SHR-1210 is a humanized monoclonal antibody, and the heavy chain is immunoglobulin G4 (IgG4), the light chain is immunoglobulin κ (IgK). SHR-1210 specifically binds to PD-1 and blocks the interaction of PD-1 with its ligand (PD-L1), allowing T cells to recover against tumor immune responses.
The safety of SHR-1210 will be assessed by ongoing reviews of clinical laboratory tests, Eastern Cooperative Oncology Group (ECOG) performance status, physical examination, electrocardiogram (ECG), and adverse events. Evaluations of immune safety will also be conducted (immune-related adverse events (AEs), or labs of autoimmune sera, inflammatory events, and immunogenicity). Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.
Tumor response will be assessed by radiographic examination in screening visit and every 2 cycles after first dose.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- RenJiH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged >= 18 years, male or female;
- Histologically or Cytologically confirmed metastatic pancreatic adenocarcinoma;
- Patients have never received systematical anti-cancer therapy;
- Based on Response Evaluation Criteria In Solid Tumors (RECIST1.1), there should be at least one measurable lesion which has never received local treatment like radiotherapy(The lesion located in previous radiotherapy areas can also be selected as target lesions if the progress confirmed.)
- ECOG:0-1;
- Expected survival>=12 weeks;
- Essential organs function must meet the following criteria (Any blood products, growth factor, leucocyte promoting drugs, platelet promoting drugs, drugs for anemia are not allowed in 14 days before the first use of the experimental medication):
1) Absolute neutrophil count(ANC) >= 1.5x10^9/L 2) Platelet >= 85x10^9/L 3) Hemoglobin >= 90g/L 4) Serum Albumin >= 30g/L 5) Total bilirubin <= 2.0 ULN (Biliary obstructive patients after biliary drainage <= 2.5 ULN), AST and ALT <= 3.0 ULN (patients with liver metastasis <= 5 ULN); 6) Creatinine clearance rate >60 mL/min; 7) Activated Partial Thromboplastin Time and International Standardized Ratio <= 1.5 ULN (Patients using stable dose of anticoagulant therapy such as low molecular weight heparin or warfarin and INR is within the expected range of anticoagulants can be selected.)
Exclusion Criteria:
- Patients with central nervous system metastasis.
- Patients only have local advanced diseases.
- Patients have uncontrolled pleural, pericardial or abdominal effusion requiring drainage.
- Patients with history of allergy to monoclonal antibodies, any component of SHR-1210, paclitaxel(Albumin Bound) and Gemcitabine.
- Patients have ever received anti PD-1 or anti PD-L1 therapy in the past.
- Patients have accepted any experimental medication.within 4 weeks before the first dose of our experimental medication administration.
- Patients are enrolled in another clinical trial except for observational clinical trial (Non-interventional) or the follow-up of the interventional clinical trial.
- Patients accepted the last dose of anti-cancer therapy (including radiotherapy) within 4 weeks before the first dose of experimental medication administration.
- Patients who need corticosteroid or other immunosuppressive agents.
- Patients who ever received anti-cancer vaccine or have received live vaccine within 4 weeks before the first dose of administration.
- Patients who have received major surgery within 4 weeks before the first dose of administration.
- Patients with active autoimmune diseases, history of autoimmune diseases.
- History of immunodeficiency, including HIV positive test, or other acquired, congenital immunodeficiency disorders, or history of organ transplantation and allogeneic bone marrow transplantation.
- Patients with uncontrolled cardiovascular clinical symptoms or diseases.
- Severe infections occurred within 4 weeks before the first administration.
- History of interstitial lung disease and non- infectious pneumonia.
- Patients with active pulmonary tuberculosis (APTB) infection confirmed by medical history or CT examination.
- Patients with active hepatitis B or hepatitis C.
- Patients with any other malignant tumors diagnosed within 5 years before the first administration.
- Pregnant or lactating women.
- According to the researchers, participants have other factors that may force them to end up the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-120, Paclitaxel-albumin and Gemcitabine
Subjects receive SHR-1210 200mg (Day 1) and Paclitaxel-albumin 125mg/m2 (Day1 and Day8) and gemcitabine 1000mg/m2 (Day 1 and Day 8) of each 21-day cycle for at most 6 cycles until documented PD or intolerable adverse event or new anti-cancer treatment or loss to follow-up or death. Subjects receive SHR-1210 200mg (Day1) to maintain after 6 cycles treatment without PD or listed situation to terminate. |
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR:Objective Response Rate by IRC
Time Frame: through study completion, an average of 2 year
|
objective response rate evaluated by Independent Review Committee using radiographic examination according to RECIST1.1
|
through study completion, an average of 2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DCR: disease control rate
Time Frame: through study completion, an average of 2 year
|
partial rate of subjects evaluated as CR/PR/SD in all subjects
|
through study completion, an average of 2 year
|
OS: overall survival
Time Frame: through study completion, an average of 2 year
|
time from randomization to death
|
through study completion, an average of 2 year
|
ORR:Objective Response Rate by investigator
Time Frame: through study completion, an average of 2 year
|
objective response rate evaluated by investigator using radiographic examination according to RECIST1.1
|
through study completion, an average of 2 year
|
DoR:duration of response
Time Frame: through study completion, an average of 2 year
|
time firstly evaluated as CR or PR to time firstly evaluated as PD
|
through study completion, an average of 2 year
|
PFS: progression-free survival
Time Frame: through study completion, an average of 2 year
|
time from randomization to progression
|
through study completion, an average of 2 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Liwei Wang, MD, RenJi Hospital
Publications and helpful links
General Publications
- Jiujie Cui, Haiyan Yang, Jiong Hu, Jiayu Yao, Yu Wang, Yiyi Liang, Yongchao Wang, Feng Jiao, Xiaofei Zhang, Xiao Zhang, Ting Han, Tiebo Mao, Qing Xia, Xiuying Xiao, Li-Wei Wang. Anti-PD-1 antibody combined with albumin-bound paclitaxel and gemcitabine (AG) as first-line therapy and Anti-PD-1 monotherapy as maintenance in metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 39, 2021 (suppl 15; ASCO2021 abstr e16218).
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Gemcitabine
Other Study ID Numbers
- CPOG1210-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer Stage IV
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Panbela Therapeutics, Inc.CompletedPancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Stage IV Pancreatic CancerUnited States, Australia
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
University of ChicagoNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Malignant Gastrointestinal Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Gallbladder Carcinoma | Stage IV Gallbladder Cancer | Stage IV Gastric Cancer | Stage IIIA Gallbladder Cancer | Stage... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); National Institute of Nursing Research (NINR)CompletedStage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic CancerUnited States
-
Jerome Canady, M.D.Active, not recruitingStage IV Lung Cancer | Stage IV Bladder Cancer | Stage IV Pancreatic Cancer | Recurrent Malignant Solid Neoplasm | Stage IV Breast Cancer | Stage IV Renal Cell Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Stage IV Non-small Cell Lung Cancer | Stage... and other conditionsUnited States
-
Emory UniversityIpsen; Taiho Oncology, Inc.RecruitingGastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditionsUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Asan Medical... and other collaboratorsCompletedStage IV Lung Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Pediatric Brain Tumor | Stage IV Colon Cancer | Stage IV Gastric Cancer | Stage IV Liver Cancer | Malignant Hematologic Neoplasm | Pediatric Solid Tumor | Pediatric Lymphoma | Biliary Cancer Metastatic | Pediatric LeukemiaKorea, Republic of
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8United States
Clinical Trials on Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin
-
Sun Yat-sen UniversityChongqing University Cancer Hospital; Jiangxi Provincial Cancer Hospital; Shenzhen... and other collaboratorsRecruitingNasopharyngeal CarcinomaChina
-
Zhigang LiJiangsu HengRui Medicine Co., Ltd.Not yet recruitingLocally Advanced Resectable Esophageal Squamous Cell CarcinomaChina
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant ChemoimmunotherapyChina
-
Huazhong University of Science and TechnologyActive, not recruitingGastric Cancer | GastroEsophageal CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingEarly Stage Non-small Cell Lung CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingRecurrent or Metastatic Cervical CancerChina
-
Guangzhou Institute of Respiratory DiseaseJiangsu HengRui Medicine Co., Ltd.; BGI-ShenzhenCompletedEsophageal Squamous Cell Carcinoma | ImmunotherapyChina
-
Xuanwu Hospital, BeijingUnknownNon-small Cell Lung Cancer | PD-1 Antibody | Lung Cancer Stage II
-
China Medical University, ChinaUnknownAdvanced Gastric CancerChina
-
Peking UniversityUnknown